Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

84 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I study of pazopanib in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study.
Shibata SI, Chung V, Synold TW, Longmate JA, Suttle AB, Ottesen LH, Lenz HJ, Kummar S, Harvey RD, Hamilton AL, O'Neil BH, Sarantopoulos J, LoRusso P, Rudek MA, Dowlati A, Mulkerin DL, Belani CP, Gandhi L, Lau SC, Ivy SP, Newman EM. Shibata SI, et al. Among authors: sarantopoulos j. Clin Cancer Res. 2013 Jul 1;19(13):3631-9. doi: 10.1158/1078-0432.CCR-12-3214. Epub 2013 May 7. Clin Cancer Res. 2013. PMID: 23653147 Free PMC article. Clinical Trial.
Phase 1 study of AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adults with advanced solid tumors.
Mita AC, Takimoto CH, Mita M, Tolcher A, Sankhala K, Sarantopoulos J, Valdivieso M, Wood L, Rasmussen E, Sun YN, Zhong ZD, Bass MB, Le N, LoRusso P. Mita AC, et al. Among authors: sarantopoulos j. Clin Cancer Res. 2010 Jun 1;16(11):3044-56. doi: 10.1158/1078-0432.CCR-09-3368. Epub 2010 May 25. Clin Cancer Res. 2010. PMID: 20501621 Clinical Trial.
Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study.
Ramalingam SS, Kummar S, Sarantopoulos J, Shibata S, LoRusso P, Yerk M, Holleran J, Lin Y, Beumer JH, Harvey RD, Ivy SP, Belani CP, Egorin MJ. Ramalingam SS, et al. Among authors: sarantopoulos j. J Clin Oncol. 2010 Oct 10;28(29):4507-12. doi: 10.1200/JCO.2010.30.2307. Epub 2010 Sep 13. J Clin Oncol. 2010. PMID: 20837947 Free PMC article. Clinical Trial.
Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study.
Leal TB, Remick SC, Takimoto CH, Ramanathan RK, Davies A, Egorin MJ, Hamilton A, LoRusso PA, Shibata S, Lenz HJ, Mier J, Sarantopoulos J, Mani S, Wright JJ, Ivy SP, Neuwirth R, von Moltke L, Venkatakrishnan K, Mulkerin D. Leal TB, et al. Among authors: sarantopoulos j. Cancer Chemother Pharmacol. 2011 Dec;68(6):1439-47. doi: 10.1007/s00280-011-1637-5. Epub 2011 Apr 9. Cancer Chemother Pharmacol. 2011. PMID: 21479634 Free PMC article.
Pharmacokinetics and safety of bortezomib in patients with advanced malignancies and varying degrees of liver dysfunction: phase I NCI Organ Dysfunction Working Group Study NCI-6432.
LoRusso PM, Venkatakrishnan K, Ramanathan RK, Sarantopoulos J, Mulkerin D, Shibata SI, Hamilton A, Dowlati A, Mani S, Rudek MA, Takimoto CH, Neuwirth R, Esseltine DL, Ivy P. LoRusso PM, et al. Among authors: sarantopoulos j. Clin Cancer Res. 2012 May 15;18(10):2954-63. doi: 10.1158/1078-0432.CCR-11-2873. Epub 2012 Mar 6. Clin Cancer Res. 2012. PMID: 22394984 Free PMC article. Clinical Trial.
Safety and pharmacokinetics of ganitumab (AMG 479) combined with sorafenib, panitumumab, erlotinib, or gemcitabine in patients with advanced solid tumors.
Rosen LS, Puzanov I, Friberg G, Chan E, Hwang YC, Deng H, Gilbert J, Mahalingam D, McCaffery I, Michael SA, Mita AC, Mita MM, Mulay M, Shubhakar P, Zhu M, Sarantopoulos J. Rosen LS, et al. Among authors: sarantopoulos j. Clin Cancer Res. 2012 Jun 15;18(12):3414-27. doi: 10.1158/1078-0432.CCR-11-3369. Epub 2012 Apr 17. Clin Cancer Res. 2012. PMID: 22510349 Clinical Trial.
Phase I study of GRN1005 in recurrent malignant glioma.
Drappatz J, Brenner A, Wong ET, Eichler A, Schiff D, Groves MD, Mikkelsen T, Rosenfeld S, Sarantopoulos J, Meyers CA, Fielding RM, Elian K, Wang X, Lawrence B, Shing M, Kelsey S, Castaigne JP, Wen PY. Drappatz J, et al. Among authors: sarantopoulos j. Clin Cancer Res. 2013 Mar 15;19(6):1567-76. doi: 10.1158/1078-0432.CCR-12-2481. Epub 2013 Jan 24. Clin Cancer Res. 2013. PMID: 23349317 Clinical Trial.
A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors.
Rodon J, Tawbi HA, Thomas AL, Stoller RG, Turtschi CP, Baselga J, Sarantopoulos J, Mahalingam D, Shou Y, Moles MA, Yang L, Granvil C, Hurh E, Rose KL, Amakye DD, Dummer R, Mita AC. Rodon J, et al. Among authors: sarantopoulos j. Clin Cancer Res. 2014 Apr 1;20(7):1900-9. doi: 10.1158/1078-0432.CCR-13-1710. Epub 2014 Feb 12. Clin Cancer Res. 2014. PMID: 24523439 Free article. Clinical Trial.
84 results